We are live on
!
Find out more
Lazard Asset Management Portfolio holdings
AUM
$60.8B
1-Year Est. Return
22.47%
This Fund
S&P 500
This Quarter
Est. Return
+5.89%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+302.07%
AUM
$47.8B
AUM Growth
+$3.07B
(+6.9%)
Cap. Flow
-$507M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
17.74%
Holding
1,131
New
130
Increased
292
Reduced
306
Closed
143
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$526M |
| 2 |
Ally Financial
ALLY
|
+$198M |
| 3 |
CSX Corp
CSX
|
+$191M |
| 4 |
NetEase
NTES
|
+$173M |
| 5 |
Norwegian Cruise Line
NCLH
|
+$171M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$262M |
| 2 |
CVS Health
CVS
|
+$240M |
| 3 |
Mastercard
MA
|
+$204M |
| 4 |
McKesson
MCK
|
+$201M |
| 5 |
Molson Coors Class B
TAP
|
+$171M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 14.83% |
| 2 | Communication Services | 13.94% |
| 3 | Technology | 12.15% |
| 4 | Financials | 10.5% |
| 5 | Energy | 9.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
SITE Centers
SITC
$236M
| $3.69M | 0.01% |
162,266
+84,429
| +108% | +$1.87M |
|
477
Cigna
CI
$78.4B
| $3.66M | 0.01% |
39,775
| – | – |
|
478
Precigen
PGEN
$1.94B
| $3.63M | 0.01% |
151,197
-4,922
| -3% | -$99.8K |
|
|
SNP
479
DELISTED
CHINA PETROLEUM & CHEMICAL CORPORATION ADS (REP 100 ORDINARY H SHARES)
SNP
| $3.6M | 0.01% |
37,840
+13,140
| +53% | +$1.2M |
|
480
Williams-Sonoma
WSM
$27.5B
| $3.59M | 0.01% |
+100,000
| New | +$3.29M |
|
481
iShares MSCI EAFE ETF
EFA
$76.4B
| $3.59M | 0.01% |
52,488
| – | – |
|
482
Amdocs
DOX
$6.03B
| $3.58M | 0.01% |
77,289
+68,217
| +752% | +$3.21M |
|
|
IOC
483
DELISTED
Interoil Corporation
IOC
| $3.54M | 0.01% |
55,298
| – | – |
|
484
JetBlue
JBLU
$2.16B
| $3.53M | 0.01% |
325,606
-277,395
| -46% | -$2.56M |
|
485
Melco Resorts & Entertainment
MLCO
$2.21B
| $3.47M | 0.01% |
97,155
+16,295
| +20% | +$563K |
|
486
Essex Property Trust
ESS
$19.1B
| $3.46M | 0.01% |
18,703
+5,843
| +45% | +$1.03M |
|
487
Corning
GLW
$107B
| $3.42M | 0.01% |
155,774
+136,474
| +707% | +$2.89M |
|
|
AIV
488
Aimco
AIV
$377M
| $3.4M | 0.01% |
791,195
+330,345
| +72% | +$1.37M |
|
489
Public Service Enterprise Group
PEG
$38.7B
| $3.38M | 0.01% |
82,949
+70,549
| +569% | +$2.74M |
|
|
TMH
490
DELISTED
Team Health Holdings Inc
TMH
| $3.38M | 0.01% |
+67,654
| New | +$3.27M |
|
|
WP
491
DELISTED
Worldpay, Inc.
WP
| $3.35M | 0.01% |
99,683
+15,956
| +19% | +$492K |
|
492
Gaming and Leisure Properties
GLPI
$13B
| $3.33M | 0.01% |
97,951
+26,196
| +37% | +$915K |
|
493
Broadcom
AVGO
$1.76T
| $3.18M | 0.01% |
441,480
-262,980
| -37% | -$1.77M |
|
494
Skyworks Solutions
SWKS
$9.21B
| $3.17M | 0.01% |
67,465
+41,301
| +158% | +$1.74M |
|
|
WW
495
DELISTED
WW International
WW
| $3.1M | 0.01% |
+153,655
| New | +$3.29M |
|
496
Southern Company
SO
$108B
| $3.06M | 0.01% |
67,499
+41,809
| +163% | +$1.85M |
|
|
MPT
497
Medical Properties Trust
MPT
$2.84B
| $3.05M | 0.01% |
230,628
+108,700
| +89% | +$1.44M |
|
498
Analog Devices
ADI
$172B
| $2.97M | 0.01% |
+55,000
| New | +$2.91M |
|
499
State Street Industrial Select Sector SPDR ETF
XLI
$32.2B
| $2.97M | 0.01% |
+55,000
| New | +$2.94M |
|
|
PDLI
500
DELISTED
PDL BioPharma, Inc.
PDLI
| $2.96M | 0.01% |
305,600
-63,894
| -17% | -$569K |
|
Similar funds
QCM
Lazard Asset Management's Q2 2014 Portfolio in Review
As of Q2 2014, Lazard Asset Management held 1,131 positions worth $47.8B, up 6.9% from $44.8B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Lazard Asset Management's Q2 2014 filing shows 130 new, 292 increased, 306 reduced and 143 closed positions. Its largest new stake was Ally Financial: 8,153,883 shares worth $195M. The largest sale was Gilead Sciences, an estimated $262M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 16% a quarter earlier, followed by Communication Services and Technology.
- Lazard Asset Management's largest Q2 2014 buy was Ally Financial: 8,153,883 shares worth $195M.
- Lazard Asset Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $526M increase.
- Lazard Asset Management's biggest Q2 2014 reduction was Gilead Sciences, cutting an estimated $262M.
- Lazard Asset Management fully exited Mastercard in Q2 2014, selling an estimated $204M.
- Lazard Asset Management's ten largest holdings make up 18% of its $47.8B portfolio in Q2 2014.
- Lazard Asset Management opened 130 new positions and closed 143 in Q2 2014.
- Lazard Asset Management's portfolio value rose 6.9% quarter-over-quarter to $47.8B.
Based on Lazard Asset Management's 13F filing for Q2 2014, filed 12 Aug 2014.